NO801936L - Diagnosereagens for parasitoser og allergier, fremgangsmaate for fremstilling av reagenset, samt anvendelse derav - Google Patents

Diagnosereagens for parasitoser og allergier, fremgangsmaate for fremstilling av reagenset, samt anvendelse derav

Info

Publication number: NO801936L
Authority: NO; Norway
Prior art keywords: buffer; diagnostic; reagent; wells; parasitosis
Prior art date: 1979-06-28

Application number

NO801936A

Other languages

English (en)

Norwegian (no)

Inventor

Francisque Leynadier

Herve Luce

Original Assignee

Pasteur Institut

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-06-28

Filing date

1980-06-27

Publication date

1980-12-29

1979-06-28 Priority claimed from FR7916772A external-priority patent/FR2460481A1/fr

1980-05-27 Priority claimed from FR8011689A external-priority patent/FR2483621B2/fr

1980-06-27 Application filed by Pasteur Institut filed Critical Pasteur Institut

1980-12-29 Publication of NO801936L publication Critical patent/NO801936L/no

Links

230000007815 allergy Effects 0.000 title claims description 44
239000003153 chemical reaction reagent Substances 0.000 title claims description 40
238000000034 method Methods 0.000 title claims description 27
238000003745 diagnosis Methods 0.000 title claims description 12
239000000872 buffer Substances 0.000 claims description 63
239000000203 mixture Substances 0.000 claims description 58
239000000427 antigen Substances 0.000 claims description 53
102000036639 antigens Human genes 0.000 claims description 53
108091007433 antigens Proteins 0.000 claims description 53
206010020751 Hypersensitivity Diseases 0.000 claims description 43
210000003651 basophil Anatomy 0.000 claims description 40
208000030852 Parasitic disease Diseases 0.000 claims description 36
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 34
239000007788 liquid Substances 0.000 claims description 33
239000000243 solution Substances 0.000 claims description 32
208000026935 allergic disease Diseases 0.000 claims description 27
210000004369 blood Anatomy 0.000 claims description 27
239000008280 blood Substances 0.000 claims description 27
238000002405 diagnostic procedure Methods 0.000 claims description 25
210000004027 cell Anatomy 0.000 claims description 22
238000005119 centrifugation Methods 0.000 claims description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
239000000725 suspension Substances 0.000 claims description 15
210000000265 leukocyte Anatomy 0.000 claims description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
241000282414 Homo sapiens Species 0.000 claims description 10
238000004040 coloring Methods 0.000 claims description 10
239000012192 staining solution Substances 0.000 claims description 10
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
239000011575 calcium Substances 0.000 claims description 9
229910052791 calcium Inorganic materials 0.000 claims description 9
230000001066 destructive effect Effects 0.000 claims description 9
210000003714 granulocyte Anatomy 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 8
230000001413 cellular effect Effects 0.000 claims description 8
239000011777 magnesium Substances 0.000 claims description 8
229910052749 magnesium Inorganic materials 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
238000001035 drying Methods 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000012128 staining reagent Substances 0.000 claims description 7
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
210000004698 lymphocyte Anatomy 0.000 claims description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
229920001917 Ficoll Polymers 0.000 claims description 5
229960004830 cetylpyridinium Drugs 0.000 claims description 5
-1 cetylpyridinium halide Chemical class 0.000 claims description 5
230000003458 metachromatic effect Effects 0.000 claims description 5
230000003287 optical effect Effects 0.000 claims description 5
230000000717 retained effect Effects 0.000 claims description 5
229950000550 sodium metrizoate Drugs 0.000 claims description 5
229940043517 specific immunoglobulins Drugs 0.000 claims description 5
238000010186 staining Methods 0.000 claims description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 4
239000011521 glass Substances 0.000 claims description 4
229920000669 heparin Polymers 0.000 claims description 4
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 4
230000009467 reduction Effects 0.000 claims description 4
229950003937 tolonium Drugs 0.000 claims description 4
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 4
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
229960001484 edetic acid Drugs 0.000 claims description 3
229960002897 heparin Drugs 0.000 claims description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
238000005070 sampling Methods 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
239000001110 calcium chloride Substances 0.000 claims description 2
229910001628 calcium chloride Inorganic materials 0.000 claims description 2
235000011148 calcium chloride Nutrition 0.000 claims description 2
210000004395 cytoplasmic granule Anatomy 0.000 claims description 2
229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 6
UKIYDXCFKFLIMU-UHFFFAOYSA-M Isopaque Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I UKIYDXCFKFLIMU-UHFFFAOYSA-M 0.000 claims 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
238000009534 blood test Methods 0.000 claims 1
150000001805 chlorine compounds Chemical class 0.000 claims 1
238000012360 testing method Methods 0.000 description 13
208000009366 Echinococcosis Diseases 0.000 description 9
239000006285 cell suspension Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000012530 fluid Substances 0.000 description 8
239000002609 medium Substances 0.000 description 6
206010014096 Echinococciasis Diseases 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
201000003808 Cystic echinococcosis Diseases 0.000 description 4
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
239000003708 ampul Substances 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002390 adhesive tape Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000035931 haemagglutination Effects 0.000 description 3
238000000760 immunoelectrophoresis Methods 0.000 description 3
GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229920000742 Cotton Polymers 0.000 description 2
241000282412 Homo Species 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
238000004043 dyeing Methods 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
230000003108 parasitologic effect Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000001173 tumoral effect Effects 0.000 description 2
239000008096 xylene Substances 0.000 description 2
229920006051 Capron® Polymers 0.000 description 1
208000006968 Helminthiasis Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241000242683 Schistosoma haematobium Species 0.000 description 1
241000242680 Schistosoma mansoni Species 0.000 description 1
239000013566 allergen Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229940010048 aluminum sulfate Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
201000009361 ascariasis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000007664 blowing Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000007373 indentation Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000009593 lumbar puncture Methods 0.000 description 1
229960004712 metrizoic acid Drugs 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000012113 quantitative test Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/809—Multifield plates or multicontainer arrays
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO801936A 1979-06-28 1980-06-27 Diagnosereagens for parasitoser og allergier, fremgangsmaate for fremstilling av reagenset, samt anvendelse derav NO801936L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR7916772A FR2460481A1 (fr)	1979-06-28	1979-06-28	Nouveau reactif de diagnostic des parasitoses, procede de preparation de ce nouveau reactif et procede de diagnostic des parasitoses a l'aide dudit reactif
FR8011689A FR2483621B2 (fr)	1980-05-27	1980-05-27	Nouveau reactif de diagnostic des parasitoses et des allergies, procede de preparation de ce nouveau reactif et procede de diagnostic des parasitoses et des allergies a l'aide dudit reactif

Publications (1)

Publication Number	Publication Date
NO801936L true NO801936L (no)	1980-12-29

Family

ID=26221222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO801936A NO801936L (no)	1979-06-28	1980-06-27	Diagnosereagens for parasitoser og allergier, fremgangsmaate for fremstilling av reagenset, samt anvendelse derav

Country Status (8)

Country	Link
US (1)	US4640897A (da)
EP (1)	EP0022698B1 (da)
CA (1)	CA1166566A (da)
DE (1)	DE3071693D1 (da)
DK (1)	DK276480A (da)
ES (3)	ES8501886A1 (da)
NO (1)	NO801936L (da)
OA (1)	OA06560A (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5187099A (en) *	1986-10-29	1993-02-16	Coulter Corporation	Control slide for immunoassay kit using a low-temperature melting paraffin
US4816410A (en) *	1986-10-29	1989-03-28	Coulter Corporation	Control slide for immunoassay kit and method of making same
US4914041A (en) *	1988-02-12	1990-04-03	Beckman Instruments, Inc.	Reagent and method for detecting rheumatoid factor
EP0352026A3 (en) *	1988-07-19	1991-02-06	Ruby Pauline Bonderman	A glass slide useful as a control of standard by having several areas of differing levels or types of analytes, and devices and methods for preparing the same
GB9211902D0 (en) *	1992-06-05	1992-07-15	Food Tolerance Testing Ltd	Method of determining the allergenic response of a sample of mammalian blood to an antigen
US5290706A (en) *	1992-11-10	1994-03-01	Camiener Gerald W	Visualization system for retrieval, identification, and positioning of biological samples for subsequent microscopic examination
DE59708342D1 (en) *	1997-01-20	2002-10-31	Orpegen Pharma Gmbh	Basophilen-degranulationstest
FR2765341A1 (fr) *	1997-06-25	1998-12-31	Alain Funes	Methode pour l'analyse de l'activation des basophiles humains par mesure de l'expression membranaire du marqueur cd63
AT5044U1 (de) *	2001-05-10	2002-02-25	Medsystems Diagnostics Gmbh	Quantitativer einschritt immuntest in lyophilisierter form
US20150024427A1 (en) *	2013-07-19	2015-01-22	Rarecyte, Inc.	Solution and method for adhering suspension components to a substrate
CN111088313B (zh) *	2019-12-16	2024-05-14	中国水产科学研究院珠江水产研究所	一种用于快速固定嗜热四膜虫细胞计数的试剂及其计数方法
CN114047109B (zh) *	2022-01-11	2022-06-21	深圳市帝迈生物技术有限公司	一种样本分析仪及其计数方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3900558A (en) *	1971-06-23	1975-08-19	Richardson Merrell Inc	Method of measuring histamine release from mast cells
CH613523A5 (en) *	1975-06-27	1979-09-28	Inst Nat Sante Rech Med	Method for displaying basophils
FR2315251A1 (fr) *	1975-06-27	1977-01-21	Inst Nat Sante Rech Med	Procede et composition metachromatique pour la numeration des leucocytes, plus particulierement des basophiles
US3988115A (en) *	1975-09-18	1976-10-26	Modabber Farrokh Z	Diagnostic method for determining pathological condition by antigen-combining capacity of lymphocytes

1980
- 1980-06-26 CA CA000354881A patent/CA1166566A/fr not_active Expired
- 1980-06-26 EP EP80400959A patent/EP0022698B1/fr not_active Expired
- 1980-06-26 DK DK276480A patent/DK276480A/da not_active Application Discontinuation
- 1980-06-26 DE DE8080400959T patent/DE3071693D1/de not_active Expired
- 1980-06-27 NO NO801936A patent/NO801936L/no unknown
- 1980-06-28 ES ES492912A patent/ES8501886A1/es not_active Expired
- 1980-06-28 OA OA57146A patent/OA06560A/xx unknown
1983
- 1983-05-02 US US06/489,603 patent/US4640897A/en not_active Expired - Fee Related
- 1983-07-16 ES ES524192A patent/ES8404055A1/es not_active Expired
1984
- 1984-03-12 ES ES530527A patent/ES530527A0/es active Granted

Also Published As

Publication number	Publication date
CA1166566A (fr)	1984-05-01
EP0022698A1 (fr)	1981-01-21
OA06560A (fr)	1981-07-31
US4640897A (en)	1987-02-03
ES8504218A1 (es)	1985-04-16
EP0022698B1 (fr)	1986-08-13
ES530527A0 (es)	1985-04-16
ES524192A0 (es)	1984-04-16
DK276480A (da)	1980-12-29
ES8404055A1 (es)	1984-04-16
DE3071693D1 (en)	1986-09-18
ES492912A0 (es)	1984-12-16
ES8501886A1 (es)	1984-12-16

Publication	Publication Date	Title
Telfer	1960	The selective accumulation of blood proteins by the oocytes of saturniid moths
Advani et al.	1982	Inactivation of Kell blood group antigens by 2‐aminoethylisothiouronium bromide
NO801936L (no)	1980-12-29	Diagnosereagens for parasitoser og allergier, fremgangsmaate for fremstilling av reagenset, samt anvendelse derav
DK174032B1 (da)	2002-04-29	Sæt samt fremgangsmåde til immunometrisk dosering, der kan anvendes på hele celler
CN101387641B (zh)	2013-11-27	一种淡水鱼类肝吸虫快速免疫检测试剂盒和检测方法
US4329331A (en)	1982-05-11	Diagnostic method for detection of systemic lupus erythematosus
ES2322931T3 (es)	2009-07-02	Preparacion de esferas para pruebas de diagnostico.
Van Vleck et al.	1958	A study of the reactions of human polymorphonuclear leukocytes to various allergens
Stamm et al.	1973	Evaluation of a latex agglutination test for amoebiasis
Ben-Edet et al.	2004	Diagnosis of plasmodium falciparum malaria in children using the immuno-chromatographic diagnostic technique
US3777014A (en)	1973-12-04	Method and reagents for the diagnosis of viral diseases
RU2339038C2 (ru)	2008-11-20	Способ прижизненной диагностики трихинеллеза плотоядных и всеядных животных
Cohen	1955	Immunological studies of the serum proteins of some reptiles
Prakash	2016	Lab manual on blood analysis and medical diagnostics
Anti-A	0	Anti-A Monoclonal Reagent, Anti-B Monoclonal Reagent, Anti-AB Monoclonal Reagent, Anti-D IgG/IgM blend Reagent
Grundbacher	1964	Immunohemolysis as a method for quantitation of the A antigen of human erythrocytes
TEST	0	Anti-A Monoclonal Reagent, Anti-B Monoclonal Reagent, Anti-AB Monoclonal Reagent, Anti-D IgG/IgM blend Reagent
Fokou et al.	2024	Tentative Analysis of Biomarkers Associated with Filariasis in Moungo Division, Littoral, Cameroon
Sharma et al.	2019	Forensic Existence of Blood as a Dynamic Evidence
Morimoto et al.	2001	Detection of Giardia lamblia Cysts in Non-Fixed Long-Term Stored Human Feces by Direct lmmunofluorescence Assay
TEST	0	Blood Grouping Reagents: Anti-A Monoclonal Reagent, Anti-B Monoclonal Reagent, Anti-AB Monoclonal Reagent, Anti-D IgG/IgM blend Reagent
CN101792746A (zh)	2010-08-04	用于冠心病诊断的血管过氧化物酶elisa试剂盒
JPH05346428A (ja)	1993-12-27	顆粒球の迅速なカウントのためのキット及び前記キットを使用する方法
Kout et al.	1964	An attempt to assess blood groups in paleoanthropological material
McLaren	1979	The development of the enzyme linked immunosorbent assay (ELISA) for schistosomiasis and its epidemiological applications